The Food and Drug Administration (FDA)-approved an expanded repertoire of IFNβ use, namely intramuscular (IM) IFNβ-1a (Avonex, Biogen), subcutaneous (SC) IFNβ-1a (Rebif, EMD Serono), and PEGylated IFN (PEGIFN)- β-1a (Plegridy, Biogen) for the treatment of MS (17). Here, IFNB1 is linked to myeloid sarcoma.